{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:39:17Z","timestamp":1768779557199,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI14C2750"],"award-info":[{"award-number":["HI14C2750"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10549-018-4809-8","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T06:57:59Z","timestamp":1525762679000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and\/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database"],"prefix":"10.1007","volume":"171","author":[{"given":"Jung Yoon","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Ji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Pil","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Ran","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeul Hong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyong Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"4809_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(05)66544-0","journal-title":"Lancet"},{"key":"4809_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D\u2019Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD006243.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4809_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7:214\u2013220","journal-title":"Curr Cardiol Rev"},{"key":"4809_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U","volume":"39","author":"RA Minow","year":"1977","unstructured":"Minow RA, Benjamin RS, Lee ET, Gottlieb JA (1977) Adriamycin cardiomyopathy\u2013risk factors. Cancer 39:1397\u20131402","journal-title":"Cancer"},{"key":"4809_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710\u2013717","journal-title":"Ann Intern Med"},{"key":"4809_CR6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaoncol.2016.1269","volume":"2","author":"HC Chien","year":"2016","unstructured":"Chien HC, Kao Yang YH, Bai JP (2016) Trastuzumab-related cardiotoxic effects in Taiwanese women: a nationwide cohort study. JAMA Oncol 2:1317\u20131325. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.1269","journal-title":"JAMA Oncol"},{"key":"4809_CR7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"key":"4809_CR8","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869\u20132879. \n                    https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"key":"4809_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"4809_CR10","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808\u20133815. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.10.4976.6","journal-title":"J Clin Oncol"},{"key":"4809_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7497\/j.issn.2095-3941.2014.02.005","volume":"11","author":"DR Youlden","year":"2014","unstructured":"Youlden DR, Cramb SM, Yip CH, Baade PD (2014) Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 11:101\u2013115. \n                    https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2014.02.005","journal-title":"Cancer Biol Med"},{"key":"4809_CR12","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA (2004) New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57:1288\u20131294. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2004.03.012","journal-title":"J Clin Epidemiol"},{"key":"4809_CR13","doi-asserted-by":"publisher","first-page":"djv301","DOI":"10.1093\/jnci\/djv301","volume":"108","author":"HA Goldhar","year":"2016","unstructured":"Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK (2016) The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J Natl Cancer Inst 108:djv301. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv301","journal-title":"J Natl Cancer Inst"},{"key":"4809_CR14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293\u20131305. \n                    https:\/\/doi.org\/10.1093\/jnci\/djs317","journal-title":"J Natl Cancer Inst"},{"key":"4809_CR15","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366\u20133373. \n                    https:\/\/doi.org\/10.1200\/jco.2011.35.0868","journal-title":"J Clin Oncol"},{"key":"4809_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"key":"4809_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2407-7-153","volume":"7","author":"GA Viani","year":"2007","unstructured":"Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153. \n                    https:\/\/doi.org\/10.1186\/1471-2407-7-153","journal-title":"BMC Cancer"},{"key":"4809_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1517\/14740331003627441","volume":"9","author":"AJ Chien","year":"2010","unstructured":"Chien AJ, Rugo HS (2010) The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf 9:335\u2013346. \n                    https:\/\/doi.org\/10.1517\/14740331003627441","journal-title":"Expert Opin Drug Saf"},{"key":"4809_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","volume":"7","author":"L Gianni","year":"2007","unstructured":"Gianni L, Salvatorelli E, Minotti G (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7:67\u201371. \n                    https:\/\/doi.org\/10.1007\/s12012-007-0013-5","journal-title":"Cardiovasc Toxicol"},{"key":"4809_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-017-4362-x","volume":"166","author":"AF Yu","year":"2017","unstructured":"Yu AF, Mukku RB, Verma S, Liu JE, Oeffinger KC, Steingart RM, Hudis CA, Dang CT (2017) Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. Breast Cancer Res Treat 166:241\u2013247. \n                    https:\/\/doi.org\/10.1007\/s10549-017-4362-x","journal-title":"Breast Cancer Res Treat"},{"key":"4809_CR21","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1253\/circj.CJ-13-0971","volume":"77","author":"Y Sakata","year":"2013","unstructured":"Sakata Y, Shimokawa H (2013) Epidemiology of heart failure in Asia. Circ J 77:2209\u20132217","journal-title":"Circ J"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-4809-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T16:35:09Z","timestamp":1557419709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-4809-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4809"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4809-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"25 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors indicated no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The institutional review board of Korea University Anam Hospital approved and granted this study a waiver of informed consents from participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}